Key facts
- Epivara’s last known valuation is $40.0M (Jul 2025).
- It has raised $8.5M; the latest was Later Stage VC ($5.2M) in Jul 2025.
- Notable investors include US National Science Foundation, gener8tor, United States Department of Agriculture, Byron Wittenberg, First Leaf Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Epivara
- ·The full record, as it builds
Funding rounds
No funding rounds for Epivara are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epivara
Developer of a single-injection alternative to spaying and neutering surgery intended to provide a new way to fix animals without painful, risky surgeries. The company's sterilizer is a tiny capsule that helps to achieve all the benefits of neutering without the drawbacks of surgery, enabling pet owners to prevent overpopulation, reproduction-related diseases and conditions, and avoid costly surgeries.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Champaign, IL, United States
- Founded
- 2016
- Employees
- 9
- Website
- epivara.com/
- Ownership
- Privately Held (backing)
Epivara doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epivara shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epivara in its N-PORT filings yet. We sweep new filings monthly.